# MOTS-c: A Peptide Discovered Inside a Mitochondrion > MOTS-c: Research Overview — Peptide Asia — A cited research overview of MOTS-c, a mitochondrial-derived peptide studied for metabolism, exercise and aging. Mechanism, animal findings, one human observational cohort, and why no interventional human trial yet exists. **04 / RESEARCH PEPTIDE FUNDAMENTALS** Encoded not by nuclear DNA but by a short reading frame inside the mitochondrial genome — and still, more than a decade after discovery, without a single completed human interventional trial. ## The short version MOTS-c is a 16-amino-acid peptide with an unusual origin story: it is encoded by a short stretch of DNA inside the mitochondrial genome, the small set of genes mitochondria carry separately from the rest of a cell's DNA. In mouse studies it has improved glucose handling and, notably, improved physical performance in older mice, which is why it draws interest in metabolism and aging research. The honest gap here is larger than for any other compound on this desk: there is no published, completed human interventional trial for MOTS-c. The only substantial human data are observational — a study measuring naturally circulating MOTS-c levels in people with kidney disease, not a trial giving anyone the peptide [19]. It is not approved as a medicine anywhere and is sold only for laboratory research. This page is careful to keep animal findings and human findings clearly separated, and it does not suggest a dose. ## What it is MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded within a short open reading frame inside the mitochondrial 12S ribosomal RNA gene — part of the mitochondrial genome rather than the nuclear one where most genes reside. This sequence is highly conserved across mammalian species, meaning evolution has kept it nearly unchanged for a very long time, which researchers generally read as a sign that it does something functionally important. ## How it works MOTS-c's best-characterized action is on a cellular energy pathway: it inhibits a metabolic route called the folate cycle, which in turn activates an enzyme called AMPK — a master regulator that cells use to sense and respond to low energy availability. AMPK activation improves glucose uptake and insulin sensitivity, primarily in skeletal muscle. Under metabolic stress, MOTS-c does something unusual for a peptide made from mitochondrial genes: it travels from the mitochondrion into the cell nucleus and helps regulate the activity of nuclear genes, including a set of antioxidant-defence genes, in an AMPK-dependent way [22]. A 2024 study went further and identified a direct molecular target: MOTS-c binds and activates an enzyme called casein kinase 2 (CK2), with tissue-specific effects — activating CK2 in muscle while suppressing it in fat tissue — that appear to underlie its effects on muscle glucose uptake and its ability to prevent muscle wasting in mouse models [18]. ## What the research shows *The direct molecular target.* A 2024 study in mice — young, aged, on a high-fat diet, and immobilized — showed that MOTS-c directly binds and activates CK2 in cell-free systems, and that this tissue-specific modulation of CK2 activity prevented skeletal muscle atrophy and enhanced muscle glucose uptake [18]. *Exercise and aging.* In mice ranging from 2 to 22 months old, exogenous MOTS-c significantly improved treadmill running capacity, grip strength and gait, with the clearest gains in the oldest animals. The same research established that exercise itself induces the body's own MOTS-c production in skeletal muscle and circulation, positioning it as what researchers call an exercise-mimetic [21]. *Mitochondrion-to-nucleus signalling.* In human and mouse cell lines, MOTS-c was shown to move from the mitochondrion into the nucleus under metabolic stress and regulate nuclear gene expression, including antioxidant-response genes, through an AMPK-dependent interaction with the stress-response protein NRF2 — the first demonstration of this kind of retrograde signalling by a mitochondrial-encoded peptide [22]. *The one substantial human data point.* A prospective, multicentre cohort study followed 94 people on chronic hemodialysis for a median of 26.5 months. Naturally circulating MOTS-c levels were independently associated with a combined risk of death and cardiovascular events, and adding MOTS-c to a standard risk model modestly improved its predictive accuracy [19]. This is an observational association in existing patients, not a trial of giving anyone MOTS-c — an important distinction this desk keeps front and centre. *Where the field stands.* A comprehensive 2023 review of the literature synthesizes MOTS-c's mitochondrial origin, AMPK mechanism, nuclear translocation, and its roles across metabolism, stress adaptation and aging research, serving as the field's current reference point [20]. ## Reported effects, cautions & safety There is no meaningful body of anecdotal community reporting or formally documented safety-caution literature for MOTS-c comparable to the other three peptides on this desk, and this desk will not manufacture the appearance of one. What can be said, drawing on the documented state of the field rather than user reports, is this: every claim about MOTS-c improving metabolism, physical performance or aging in a living organism comes from cell or animal studies, predominantly in mice [18][21][22]. No published human interventional trial — a study that actually gives people MOTS-c and measures an outcome — currently exists; the one substantial human dataset is the hemodialysis cohort described above, which measured naturally occurring levels rather than administering the peptide [19]. There is correspondingly no established human dosing, pharmacokinetic profile, or safety record. MOTS-c is not approved by the FDA or any regulator for any use, and material sold as a research chemical carries the identity, purity and sterility uncertainties typical of an unregulated laboratory-supply product. Anti-doping authorities treat MOTS-c as a prohibited substance in elite sport, a practical consideration independent of the medical evidence. ## Where it fits in the global research map MOTS-c sits at the earliest, most preclinical edge of this desk's map — a compound whose entire human evidence base is one observational cohort study, set against a growing and increasingly mechanistic animal literature [18][19][21][22]. That gap is even wider than the one that applies to [BPC-157](/bpc-157), which at least has three small human pilot reports to its name. Both sit far from [thymosin alpha-1](/thymosin-alpha-1), approved as a medicine in dozens of countries, and [semaglutide](/semaglutide), backed by a dense, FDA-anchored trial programme. See the [comparison page](/compare) for how the evidence bases actually stack up. ![MOTS-c research illustration](/images/mots-c.webp) --- Peptide Asia draws its own map from published citations, not from borders or brochures — read it as a literature digest, never as a clinic, a shop, or a prescription.